Abeta-targeting proteins and methods of use
AssigneeDenali Therapeutics Inc.
InventorsKapil G. GADKAR, Nathalie KHOURY, Michelle E. PIZZO, Joy Yu ZUCHERO
Life of this patent
Estimating the term…
Abstract
Described are Abeta-targeting proteins comprising an Abeta-binding region, a transferrin receptor (TfR)-binding region that specifically binds a TfR with an affinity of about 900 nM to about 10,000 nM, an FcγR-binding region. Also described are method of making the Abeta-targeting proteins and methods of using the Ab eta-targeting proteins to treat neurodegenerative disorders.
Claims64
An Abeta-targeting protein comprising:
- (a) an amyloid beta (Abeta)-binding region;
- (b) a transferrin receptor (TfR)-binding region that specifically binds a TfR with an affinity of about 900 nM to about 10,000 nM;
- and
- (c) an Fcγ Receptor (FcγR)-binding region.
A nucleic acid encoding a polypeptide having at least 85% identity, at least 90% identity, or at least 95% identity, to any of SEQ ID NOs:
- 8, 10, and 17-31, wherein the encoded polypeptide has the amino acids at positions 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421, according to EU numbering scheme, as shown in Table 1.
A combination of nucleic acids comprising:
- a first nucleic acid encoding a first polypeptide having the amino acid sequence of any of SEQ ID NOs:
- 8, 10, and 17-31 and a second nucleic acid encoding a second polypeptide having the amino acid sequence of SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.